• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Life sciences >Nebivolol and airway responsiveness in the rabbit.
【24h】

Nebivolol and airway responsiveness in the rabbit.

机译：Nebivolol和兔子的气道反应性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Beta-adrenergic receptor antagonists are currently used as first-line therapy in the treatment of hypertension and angina pectoris, but are contraindicated or used with caution in patients with bronchospastic syndromes. In this study we evaluated in vivo the effects of nebivolol on airway responsiveness compared to atenolol, pindolol, and propranolol. In New Zealand white rabbits total lung resistance (R(L)) and dynamic compliance (Cdyn) were calculated. In acute protocol, the animals were intravenously injected with the beta-blockers at different doses while in the chronic protocol, animals were daily injected for 30 days. Furthermore, the changes induced by beta-blockers (higher doses) in R(L) and Cdyn after a treatment with salbutamol were calculated. In acute treatment, airway responsiveness to histamine was not modified by nebivolol at any dosage, but increased significantly following the exposure to the higher doses of the other beta-blockers. In chronic treatment, the thirty-day exposure to nebivolol, did not modify the airway responsiveness to histamine, whereas the other beta-blockers significantly increased airway responsiveness. Moreover, nebivolol affected the salbutamol-induced relaxation less markedly than other beta-blockers do. These data demonstrate that nebivolol respect the other beta-blockers used in this study, does not significantly affect the airway responsiveness, therefore it could be used in patients with both cardiovascular and bronchial diseases more safely than other beta-blockers drugs.
机译：β-肾上腺素能受体拮抗剂目前被用作治疗高血压和心绞痛的一线疗法，但在支气管痉挛综合症患者中禁用或谨慎使用。在这项研究中，我们评估了奈替洛尔与阿替洛尔，匹多洛尔和普萘洛尔相比对气道反应性的影响。在新西兰白兔中，计算了总肺阻力（R（L））和动态顺应性（Cdyn）。在急性方案中，动物以不同剂量静脉内注射β受体阻滞剂，而在慢性方案中，动物则每天注射30天。此外，计算了沙丁胺醇治疗后R（L）和Cdyn中β受体阻滞剂（较高剂量）引起的变化。在急性治疗中，奈必洛尔在任何剂量下均不会改变对组胺的气道反应性，但在暴露于更高剂量的其他β受体阻滞剂后会明显增加。在慢性治疗中，奈必洛尔暴露30天不会改变呼吸道对组胺的反应性，而其他β受体阻滞剂会显着增加呼吸道的反应性。此外，奈必洛尔对沙丁胺醇诱导的舒张作用的影响不如其他β受体阻滞剂显着。这些数据表明奈必洛尔尊重本研究中使用的其他β受体阻滞剂，不会显着影响气道反应性，因此与其他β受体阻滞剂药物相比，它可以更安全地用于患有心血管和支气管疾病的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号